Teriflunomide and Multiple sclerosis - a phase IV clinical study of FDA data

Summary:

Multiple sclerosis is reported as a side effect among people who take Teriflunomide (teriflunomide), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Vitamin D3, and have Relapsing-remitting multiple sclerosis.

The phase IV clinical study analyzes which people have Multiple sclerosis when taking Teriflunomide. It is created by eHealthMe based on reports of 5,064 people who have side effects when taking Teriflunomide from the FDA, and is updated regularly.

What is Teriflunomide?

Teriflunomide has active ingredients of teriflunomide. eHealthMe is studying from 5,067 Teriflunomide users. Check the latest studies of Teriflunomide.

What is Multiple sclerosis?

Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,088 drugs and 1,358 conditions by eHealthMe. Check the latest studies of Multiple sclerosis.

On Jul, 11, 2026

5,064 people reported to have side effects when taking Teriflunomide.
Among them, 397 people (7.84%) have Multiple sclerosis.

Could Teriflunomide cause Multiple sclerosis?

Among these 397 people:

How long have people been on Teriflunomide when they have Multiple sclerosis? *

Click here to view more results

What is the gender of people who have Multiple sclerosis when taking Teriflunomide? *

Click here to view

What is the age of people who have Multiple sclerosis when taking Teriflunomide? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Teriflunomide and have Multiple sclerosis?

- Check whether Multiple sclerosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Teriflunomide:

Teriflunomide (5,067 reports)

Multiple sclerosis treatments and more:

Multiple sclerosis (799,636 reports)

How severe was Multiple sclerosis and when was it recovered:

Multiple sclerosis in Teriflunomide

Expand to all the drugs that have ingredients of teriflunomide:

Multiple sclerosis and drugs with ingredients of teriflunomide (2,831 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Teriflunomide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Multiple sclerosis:

Multiple sclerosis (1,088 drugs)

Browse all the conditions that are associated with Multiple sclerosis:

Multiple sclerosis (1,358 conditions)

Related publications that referenced our studies

Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on teriflunomide (the active ingredients of Teriflunomide) and Teriflunomide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.